Drugs / SAMARIUM LEXIDRONAM PENTASODIUM

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) QUADRAMET — 1997-03-28 fda.gov ↗

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 1/2 NCT00478075 Background Sep 2005 → Nov 2007 plasma cell myeloma Mayo Clinic Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SAMARIUM LEXIDRONAM PENTASODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Known as CYT-424 ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Known as Quadramet ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Known as Samarium (153 sm) lexidronam pentasodium ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Known as Samarium (153sm) lexidronam ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Known as Samarium (153sm) lexidronam sodium ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Known as samarium Sm 153 lexidronam pentasodium “Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells.” NCT00478075 ↗
Known as Samarium sm 153 lexidronam pentasodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Known as Sm-153 edtmp pentasodium ChEMBL registry synonym — accepted as the source's own label CHEMBL2110561 ↗
Modality Small molecule — CHEMBL2110561 ↗
Route Intravenous “Patients receive samarium Sm 153 lexidronam pentasodium IV over 1 minute on day 1” NCT00478075 ↗